Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Clinical Trials Metabolic Disorders BioPharmaceutical

Novo's Oral Semaglutide Passes PIONEER 2, But Weight Loss Result A Bit Disappointing

Executive Summary

In second Phase III diabetes study to report, oral GLP-1 agonist semaglutide misses some weight loss goals when compared with Boehringer/Lilly's SGLT-2 inhibitor Jardiance.

You may also be interested in...



Seeking Efficiencies, Novo Nordisk To Squeeze Costs, Boost Growth Drivers

Novo Nordisk aims to offset US pricing pressures with increased cost management, freeing investment for key growth drivers like Ozempic and oral Semaglutide.

Novo Nordisk: Switch To Weekly Ozempic Has Begun, Biopharma M&A Sought

But elephant in the room –  the coming stream of readouts from Phase III PIONEER trials on oral semaglutide  in Type 2 diabetes – gets little mention at first-quarter update.

Novo Nordisk Already Plans A 'Next Generation' Oral Semaglutide - CEO

Planned next generation of oral semaglutide 'is in the early research stage', Lars Fruergaard Jorgensen tells Scrip.

Table

View full table

Related Content

Scrip

Topics

Related Companies

Tags:
Clinical Trials Metabolic Disorders BioPharmaceutical
Latest Headlines

Parkinson’s Results Further Sweeten AbbVie’s Acquisition of Cerevel

Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line

Normality Reasserts Itself For Biotech IPOs

Executives On The Move: Changes At The Top At Viatris And Clinuvel Among This Week's Announcements

See All
UsernamePublicRestriction

Register

SC123166

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By